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Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disorder and one of the leading causes of death at 
old age [1, 2]. AD affects different domains of functioning, 
including cognitive and motor functioning [2, 3]. Motor 
functioning involves the integration of various cognitive 
functions including visuospatial perception, attention, and 
planning. Deficits in these cognitive functions can therefore 
affect motor functioning, and subtle changes in motor func-
tioning could be an early indicator of cognitive decline [4]. 
Identifying patients in pre-dementia states, such as mild 
cognitive impairment (MCI), is an important clinical need 
since treatment may be more effective in early stages [1, 
5]. This has led to an increase in research on early mark-
ers for cognitive decline, including motor markers [4]. The 
relation between motor activity and dementia has received 
increasing research attention over the past years [4, 6–24]. 
Studies have shown that compared to healthy elderly, AD 
patients walk more slowly and have an increased fall risk 
[9]. In addition, research has shown that gait disturbances 
can be observed in early AD and can predict progression 
from MCI to AD [7, 8, 11, 12, 20]. Research on gait dis-
turbances as an early indicator for MCI and AD often uses 
the dual-task paradigm to explore the influence of cogni-
tive functioning on motor functioning [4, 6, 15–19]. Dual 
tasking relies on dividing attention between two distinct 
tasks, often a motor task such as walking and a cognitively 
demanding task such as counting backwards. The dual-task 
paradigm can be used to study the allocation of attentional 
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resources during a motor task and to separate the cogni-
tive and motor components of executing a movement [4]. 
MCI and AD patients typically show more pronounced 
decrements in gait when performing two tasks simultane-
ously compared to healthy elderly [15, 16, 19]. Different 
cognitive tasks have been used for dual tasking including 
simple tasks such as counting backwards [6, 16], or more 
complex tasks such as a verbal fluency [6, 16] or reciting 
alternate letters of the alphabet [17]. Generally, increasing 
cognitive effort in the dual task increases sensitivity of the 
gait assessment but in older adults an attention-demanding 
arithmetic task such as counting backwards seems to be 
more appropriate for gait analyses [18].
Several studies have explored gait-related features such 
as speed of walking, stride frequency, and length and sym-
metry of steps in elderly with and without cognitive impair-
ment during the performance of a single and a dual task 
[4, 6, 12, 15, 16, 18, 19]. In a study including 14 MCI 
patients, six AD patients, and 14 healthy control subjects, 
participants were asked to walk a distance of 45 m, while 
gait parameters were measured by means of two actigraphs 
attached at the participants’ waist [15]. AD patients were 
found to be slower than MCI patients who were found to 
be slower than healthy controls during the dual task involv-
ing walking and counting backwards. Additionally, MCI 
and mild AD patients showed deviations in other aspects 
of gait during the dual task compared to the single task, 
which were not found in healthy controls. Other studies that 
have only included MCI patients and not AD patients have 
found similar results [4, 6, 13, 16]. For instance, a study 
including 55 MCI patients found that participants walked 
significantly slower during a dual task than during a sin-
gle task [6]. Similarly, a study measuring differences in in-
home walking trajectories between 31 non-amnestic MCI 
patients and 54 healthy elderly found that individuals with 
non-amnestic MCI walked slower than healthy elderly [13]. 
Additionally, non-amnestic MCI patients showed a more 
pronounced decrease in walking speed variability over 
time than healthy controls whose walking speed variability 
remained stable. This finding suggests that walking speed 
and the variation in walking speed over time may be an 
early marker of MCI even at a state when memory func-
tions are still intact [13]. Similarly, Beauchet et al. investi-
gated stride velocity and stride-to-stride variability of stride 
time in 39 MCI patients, 33 AD patients, and 44 healthy 
elderly finding that both gait features increased during a 
dual-task condition compared to a single-task condition 
[12]. Moreover, stride-to-stride variability was found to 
be greater in MCI patients than in healthy elderly and AD 
patients in fast-pace walking suggesting that it is a specific 
feature of MCI under a fast-pace walking condition [12].
A possible explanation for the finding that individu-
als with cognitive decline show disturbances in their gait, 
particularly under dual-task conditions, is neuropathologi-
cal changes in specific brain regions involved in the plan-
ning and execution of movements and that occur in early 
stages of dementia [2, 4, 21]. For instance, one study 
found a correlation between specific gait parameters (gait 
velocity, stride time variability) and the cerebral volume 
of the motor area as well as the presence of neurochemi-
cal changes in MCI patients during single and dual tasking 
[21].
Together, the findings of the studies described above 
suggest that changes in walking parameters, such as walk-
ing speed and variability in stride time, can be detected in 
early stages of cognitive decline and can therefore be a bio-
marker of MCI. Research has only recently started to look 
into ways to measure the link between cognitive and motor 
function and to more objectively detect subtle changes that 
could indicate MCI or progression from MCI to AD. Sens-
ing technologies are used more and more to monitor and 
assess motor behavior in elderly people [25]. Most of the 
studies on gait in MCI and AD patients have employed 
pressure-point systems, such as GAITRite® System [4, 
10–12, 17, 19, 21], or passive infrared sensors [13] which 
are not always affordable for all clinical sites. A more prac-
tical and low-cost solution for gait analysis is ambulatory 
actigraphy which consists of a piezoelectric accelerometer 
designed to record body movements. Actigraphy has pre-
viously been used in the assessment of various disorders 
including sleep–wake disorders, hyperactivity disorders, 
and dementia [22–24, 26–28]. The present study aims at 
exploring the relation between gait parameters, measured 
by means of ambulatory actigraphy during a single and 
dual task, and cognitive impairment in order to obtain more 
insights into the utility of such a paradigm as an additional 
indicator for the diagnosis of MCI and early AD.
Materials and methods
This study was conducted within the European project 
Dem@care which aims at developing a multiple sensor-
based system to assess specific behaviors of people with 
dementia and to provide feedback to patients, caregivers, 
and clinicians.
Participants and procedure
Participants aged 65  years or older were recruited within 
the Dem@care protocol [29] at the Nice Memory Research 
Center located at the Geriatric Department of the Univer-
sity Hospital. The sample consisted of 24 individuals diag-
nosed with MCI, 23 individuals diagnosed with AD, and 
22 healthy controls (HC). For the AD group, the diagnosis 
was determined using the proposed diagnostic criteria from 
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Dubois et  al. [30] requiring the presence of a progressive 
episodic memory impairment and biomarker evidence. For 
the MCI group, patients were diagnosed using the Petersen 
clinical criteria [31]. In addition, subjects were required to 
have a mini-mental state examination (MMSE) [32] score 
higher than 24. Subjects were not included if they had a 
history of head trauma with loss of consciousness, history 
of lower limb surgery, arthritis, obesity (BMI higher than 
30), concomitant medication including benzodiazepines 
or antipsychotics, psychotic or aberrant motor activity 
(tremor, rigidity, Parkinsonism) as defined by the Move-
ment Disorder Society Unified Parkinson Disease Rating 
Scale [33] in order to control for any possible motor dis-
orders influencing the ability to carry out a walking task. 
The study was approved by the local ethics committee of 
the geriatric hospital in Nice, and only participants with the 
capacity to consent to the study were included. Each partic-
ipant gave informed consent prior to the study. The consent 
was only given to publish demographic and accelerometer 
data but no biomarker data.
Assessments and clinical protocol
All participants performed a single walking task (ST) that 
consisted of walking 10  m, turning around and walking 
10 m backwards. Subsequently, all participants performed 
a dual task (DT) that involved walking the same distance 
while counting backwards from 305 in steps of 1. All par-
ticipants performed the tasks in the same corridor in the 
Memory clinic, which is approximately 10 m long and 2 m 
wide. The corridor had normal daylight and a stable room 
temperature of 25 °C. During both tasks, participants wore 
a wrist-worn accelerometer from which objective measures 
for walking speed, cadence (i.e., number of steps per min-
ute), and step variance (i.e., variance in time between two 
consecutive steps) were derived. The accelerometer data 
were analyzed by determining segments of walking data 
from the raw signal, and by applying step detection using 
a step detection algorithm that selects steps based on peaks 
in the accelerometer magnitude signal using a set of heuris-
tics related to the time between consecutive steps and the 
amplitudes of the signal peaks. Neuropsychological meas-
ures included the MMSE [31], frontal assessment battery 
(FAB) [34], and trail making test (TMT) A and B [35].
Motion data acquisition and analysis
Gait was measured using a CE-marked accelerometer 
research prototype (developed by Philips Research Labora-
tories Europe), a wrist-worn device containing a 3D accel-
erometer and data storage capabilities. The accelerometer 
was worn by the participants for the duration of the trial, 
after which the actigraphy data were retrieved from the 
device by the experimenter. During the trial, the experi-
menter indicated the start and end of both the ST and DT 
condition by pressing an event button on the accelerometer, 
creating an annotation on the device such that actigraphy 
data from both tasks could be easily extracted from the 
recording.
After extracting the actigraphy data, each recording 
was linked to the participant through a participant ID, and 
the actigraphy data for the individual ST and DT were 
extracted using the event markers recorded by the device. 
The actigraphy data for the tasks were then further cleaned 
by removing any initial and trailing periods of inactivity, 
caused by, e.g. the delay between the creation of the event 
marker and the commencement of the actual task.
Gait features were then determined algorithmically, 
using a heuristics-based step detection algorithm. The 
algorithm involves cleaning the accelerometer signal with 
a bandpass filter, finding a number of peaks in the fil-
tered signal as potential steps, and creating a selection of 
the detected peaks which optimize a set of heuristic rules 
regarding the peak amplitude and distance to other peaks. 
From the detected steps, cadence was derived as the num-
ber of steps per minute, and step variance as the vari-
ance of the time between successive steps. Walking speed 
was derived as the distance traveled, divided by the time 
between the first and last step. Walking speed was derived 
as the distance traveled, divided by the time between the 
first and last step. A more detailed explanation of the algo-
rithm and its performance on a previous dataset can be 
found in [36].
Statistical analysis
Statistical analysis was performed using SPSS 23. Analy-
ses included Chi-square test, one-way analysis of variance 
(ANOVA), mixed between-within subjects ANOVA, and 




The study included a total of 69 participants of which 23 
individuals were diagnosed with AD (mean age = 77 years 
± 9, MMSE = 17 ± 4.6), 24 individuals were diagnosed with 
MCI (mean age = 75 ± 9, MMSE = 24.8 ± 3.2), and 22 were 
healthy controls (mean age = 73 ± 7, MMSE = 28.4 ± 1.5). 
Demographic information and neuropsychological test 
results for the three groups are presented in Table 1.
There was no significant difference between the three 
groups in gender [χ²(2, 67) = 3.63, p = .163] or age [F(2, 
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66) = 1.63, p = .204]. Information about the MMSE was 
available for 67 participants. As expected, individuals 
diagnosed with AD had a lower MMSE [N = 23, 
mean = 17 (± 4.62)] than individuals diagnosed with MCI 
and HC, and individuals diagnosed with MCI [N = 24, 
mean = 24.75 (± 3.18)] had a lower MMSE than HC 
[N = 20, mean = 28.35 (± 1.5)]. All differences were sta-
tistically significant [F(2,66) = 63.23, p < .0001]. Infor-
mation about the different subscales of the MMSE [24] 
was available for 47 participants.1 As shown in Table 2, 
the differences between the HC and MCI are rather small 
and the differences between the HC and AD seem to be 
particularly pronounced in the temporal, attention and 
calculation, and recall subscores. A one-way ANOVA 
revealed significant differences for all subscales2 (orien-
tation in time: F(2,46) = 24.47, p < .0001; orientation in 
place: F(2,46) = 22.1, p < .0001; registration: 
F(2,46) = 4.17, p = .022; attention and calculation: 
F(2,46) = 11.56, p < .0001; recall: F(2,46) = 23.52, 
p < .0001; language: F(2,46) = 9.24, p < .0001; and com-
plex commands: F(2,45) = 7.25, p = .002). Post hoc tests 
revealed a significant difference between HC and AD 
(p < .0001) and MCI and AD (p < .0001) for the orienta-
tion in time subtest, between the HC and AD (p < .0001) 
1 Information about the MMSE complex commands subscale was 
only available for 46 participants.
2 When applying Bonferroni correction in order to account for mul-
tiple comparisons, the difference between groups for the registration 
subscale is no longer significant (for an alpha of 0.007).
and MCI and AD (p < .0001) for the orientation in place 
subtest, between MCI and AD (p = .033) for the registra-
tion subtest, between HC and AD (p < .0001) and MCI 
and AD (p = .008) for the attention and calculation sub-
test, between HC and MCI (p = .001), between HC and 
AD (p < .0001) and between MCI and AD (p = .003) for 
the recall subtest, between HC and AD (p = .002) and 
MCI and AD (p = .002) for the language subtest, and 
between HC and AD (p = .013) and MCI and AD 
(p = .003) for the complex commands subtest  (Table 3).
Information about the FAB was available for 55 par-
ticipants. Post hoc tests showed that participants diag-
nosed with AD [N = 18, mean = 10.89 (± 3.94)] had 
significantly lower scores on the FAB than individu-
als diagnosed with MCI [N = 20, mean = 15.1 (± 1.74), 
F(2,54) = 18.32, p < .0001] and HC [N = 17, mean = 15.94 
(± 1.78), F(2,54) = 18.32, p < .0001].
Information about the TMT was available for 46 par-
ticipants for version A and for 39 participants for ver-
sion B. Information about the TMT A was available for 
15 AD patients of whom three took so long that they 
were not asked to perform version B and who were 
therefore excluded from the analyses. When excluding 
these three patients, there was no difference between the 
three groups in time needed to perform version A of the 
TMT (F(2,42) = 2.58, p = .088). A one-way ANOVA did, 
however, find a difference between groups for the TMT 
B [F(2,37) = 12.22, p < .0001]. Post hoc tests revealed 
that AD patients [N = 7, mean = 279.29  s, (± 64.05  s)] 
needed significantly longer to complete the TMT B than 
both MCI patients [N = 15, mean = 171.73 s, (± 94.78 s), 
Table 1  Demographic information and neuropsychological tests for three groups
HC healthy control subjects, MCI mild cognitive impairment subjects, AD Alzheimer’s disease subjects, MMSE mini-mental state examination, 
FAB frontal assessment battery, TMT A trail making test version A, TMT B trail making test version B
Gender (male/
female)




HC 5/15 73 (SD = 7) 28.35 (SD = 1.5) 15.94 (SD = 1.78) 45.38 (SD = 15.2) 118 (SD = 45.7)
MCI 8/16 75 (SD = 9) 24.75 (SD = 3.18) 15.1 (SD = 1.74) 56.4 (SD = 19.1) 171.73 (SD = 94.78)
AD 12/11 77 (SD = 9) 17 (SD = 4.62) 10.89 (SD = 3.94) 66.58 (SD = 37.67) 279.29 (SD = 64.05)
Table 2  Scores on MMSE subscales for three groups
HC healthy control subjects, MCI mild cognitive impairment subjects, AD Alzheimer’s disease subjects, MMSE mini-mental state examination, 
SD standard deviation
Orientation in time Orientation in place Registration Attention and 
calculation
Recall Language Complex commands
HC 5 (SD = 0) 5 (SD = 0) 3 (SD = 0) 4.55 (SD = 0.82) 2.91 (SD = 0.3) 7.64 (SD = 0.67) 1 (SD = 0)
MCI 4.25 (SD = 1.48) 4.25 (SD = 0.91) 3 (SD = 0) 3.35 (SD = 1.6) 1.6 (SD = 1) 7.45 (SD = 0.61) 1 (SD = 0)
AD 1.94 (SD = 1.29) 2.75 (SD = 1.18) 2.69 (SD = 0.6) 1.69 (SD = 1.85) 0.56 (SD = 0.96) 6.56 (SD = 0.89) 0.67 (SD = 0.49)
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p = .007] and HC [N = 16, mean = 118  s, (± 45.7  s), 
p < .0001].
All participants were slower during the DT than dur-
ing the ST (see Fig. 1). Interestingly, there seems to be a 
steeper increase in duration (i.e., a decrease in walking 
speed) from HC to MCI than from MCI to AD for both 
the ST and the DT. A mixed between-within ANOVA 
found a significant main effect for walking speed (Wilks’s 
Lambda = 0.76, F(1,66) = 20.89, p < .0001, partial eta 
squared = 0.24) with all groups showing a difference in 
walking speed between the ST and the DT. The difference 
between groups was significant [F(1,66) = 4.24, p = .019, 
partial eta squared = 0.114]. Post-hoc tests revealed that the 
difference in walking speed between the ST and DT dif-
fered between the HC [22.62 (± 3.03) vs. 26.46 (± 6.42)] 
and the AD group [26.34 (± 5.74) vs. 31.91 (± 7.79), 
p = .026] with the increase in duration (i.e., the decrease 
in walking speed) from the ST to the DT being greater for 
the AD patients. Although the increase in duration (i.e., the 
decrease in walking speed) from ST to DT was also greater 
for MCI [25.88 (± 7.7) vs. 30.95 (± 10)] patients than for 
HC, the difference between these two groups failed to reach 
significance (p = .072). No correlations were found between 
DT duration and neuropsychological measures of aspects 
of attention such as the MMSE subscale attention and cal-
culation (r  =−.19) and the TMT B (r  = .294) or measures 
of motor performance such as the MMSE subscale complex 
commands (r =−.029).
All participants had a lower cadence during the 
DT than the ST (see Fig.  2). The difference in cadence 
between the ST and the DT is more pronounced for 
the MCI and AD patients than for the HC. A mixed 
between-within ANOVA found a significant main effect 
for cadence [Wilks’s Lambda = 0.57, F(1,66) = 50.28, 
p < .0001, partial eta squared = 0.432] with all groups 
showing a difference in cadence between the ST and the 
Table 3  Walking speed, cadence and step variance for three groups
HC healthy control subjects, MCI mild cognitive impairment subjects, AD Alzheimer’s disease subjects, MMSE mini-mental state examination, 









Step variance ST Step variance DT
HC 22.62 (SD = 3.03) 26.46 (SD = 6.4) 101.57 (SD = 12.69) 95.98 (SD = 14.03) 0.045 (SD = 0.049) 0.039 (SD = 0.054)
MCI 25.88 (SD = 7.7) 30.95 (SD = 10) 99.95 (SD = 8.99) 87.28 (SD = 14.18) 0.057 (SD = 0.045) 0.068 (SD = 0.053)
AD 26.34 (SD = 5.75) 31.91 (SD = 7.79) 97.19 (SD = 11.06) 84.84 (SD = 13.44) 0.067 (SD = 0.071) 0.102 (SD = 0.099)
Fig. 1  Duration (in seconds 
indicated on the Y axis) speed 
during the ST (blue) and the 
DT (green). HC healthy control 
subjects, MCI mild cogni-
tive impairment subjects, AD 
Alzheimer’s disease subjects, 
ST single-task condition, DT 
dual-task condition
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DT. The difference between groups did not reach statis-
tical significance [F(2,66) = 2.89, p = .062, partial eta 
squared = 0.081]. No or low correlations were found 
between DT cadence and neuropsychological measures of 
aspects of attention such as the MMSE subscale attention 
and calculation (r = .125) and the TMT B (r = −326) or 
measures of motor performance such as the MMSE sub-
scale complex commands (r = .037).
HC seem to have a smaller step variance and differ-
ence in step variance between ST and DT than MCI 
and AD patients (see Fig.  3). A mixed between-within 
ANOVA did, however, not find a significant main effect 
for step variance [Wilks’s Lambda = 0.97, F(1,65) = 1.73, 
p = .193, partial eta squared = 0.026]. There was a signifi-
cant difference between groups [F(2,65) = 4.2, p = .019, 
partial eta squared = 0.115]. Post hoc tests revealed 
that the difference in step variance between the ST and 
DT differed between the HC [0.044 (± 0.05) vs. 0.039 
(± 0.054)] and the AD group [0.067 (± 0.07) vs. 0.102 
(± 0.099), p = .015] with the increase in step variance 
from the ST to the DT being greater for the AD patients. 
No or low correlations were found between DT step 
variance and neuropsychological measures of aspects of 
attention such as the MMSE subscale attention and calcu-
lation (r = −.211) and the TMT B (r = .348) or measures 
of motor performance such as the MMSE subscale com-
plex commands (r = −.061).
Discussion
The findings of this study add to the growing body of 
research on the interaction between cognitive function 
and motor performance and show that there are changes in 
gait parameters that may help distinguish healthy elderly 
from elderly with cognitive impairment. These changes 
were detectable with an actigraph which seems to be a 
useful tool combined with the dual-task paradigm for 
gait assessment in clinical practice. As mentioned previ-
ously, actigraphy has already been proven to be of inter-
est for the evaluation of behavioral symptoms in dementia 
patients such as apathy [22] or agitation [23]. For example, 
recently, Valembois et  al. investigated the value of wrist 
actigraphy as a measure of disorder in motor behavior in 
183 elderly people with dementia finding that motor activ-
ity levels can distinguish dementia patients with apathy and 
dementia patients with aberrant motor behavior [24]. We 
were interested in the effect of performing a dual task on 
gait parameters given that dual tasking represents a cogni-
tive challenge since it requests the allocation of attentional 
resources to concomitant tasks. Although we found differ-
ences between the single and dual tasks as well as between 
healthy elderly and AD patients, we only found significant 
differences between patient groups for walking speed and 
not for cadence and step variance. It seems that changes in 
gait induced by simultaneously performing a cognitive task 
between healthy elderly and individuals with MCI are so 
Fig. 2  Cadence (number of 
steps per minute indicated on 
the Y axis) during the ST (blue) 
and the DT (green). HC healthy 
control subjects, MCI mild cog-
nitive impairment subjects, AD 
Alzheimer’s disease subjects, 
ST single-task condition, DT 
dual-task condition
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subtle that they are difficult to measure with an actigraph. 
The changes may become more salient and, thus easier to 
detect when patients progress to more severe stages of the 
disease. This is in line with previous findings. Schwenk 
et al. state in their review on gait parameters for frailty in 
elderly that gait speed showed the highest effect size to 
discriminate between different frailty status groups which 
suggests that this parameter is particularly informative and 
plays a significant role in gait analysis in elderly [37].
Although significant dual-task decrements have been 
demonstrated in AD [8, 10, 14], studies on the effects of 
dual tasking in MCI have not yield conclusive results. For 
instance, while Maquet et  al. found reduced stride fre-
quency and walking speed in MCI patients compared to 
healthy control subjects [15], Muir et  al. did not find any 
gait differences between MCI patients and healthy control 
subjects [38]. These inconclusive results may be caused 
by several factors. First, the distance participants are asked 
to walk and the cognitive task they are asked to perform 
during dual tasking differ between studies. The Muir et al. 
study demonstrated that the dual task costs for two different 
cognitive tasks, i.e., naming animals and serial subtractions 
of seven, were comparable between AD and MCI patients. 
Nevertheless, it is possible that in the present study the 
cognitive task was too easy for participants with MCI and 
future research would benefit from using various cognitive 
tasks with variable difficulty levels. Second, the measure 
used to assess gait parameters as well as the algorithms 
used to analyze these parameters differ between studies. 
When it comes to actigraphy, the position of the placed 
accelerometer can have an important impact on reliabil-
ity and quality of the measurement. As mentioned above, 
research has shown that a wrist-worn accelerometer can 
reliably distinguish between dementia patients with apathy 
and aberrant motor behavior and dementia patients who 
do not show these neuropsychiatric symptoms [24]. How-
ever, to measure gait parameters, more accurate measure-
ments may be obtained when attaching the accelerometer 
to the participant’s waist, which was the case in the study 
of Maquet et al. Consequently, it is possible that the accel-
erometer on the participants’ wrist did not pick up subtle 
changes in gait parameters and is therefore not sensitive 
enough for the specific purpose of measuring gait during 
the performance of a dual task. An important limitation of 
our study is therefore the use of a wrist-worn accelerom-
eter. A third explanation is that gait impairments in MCI 
patients are too small to detect with actigraphy and that the 
dual-task paradigm is not sensitive enough for early MCI 
screening [8, 16] but rather for more advanced stages [37]. 
As described above, changes may become more salient and, 
thus easier to detect when patients progress to more severe 
stages of the disease. It is interesting to mention in this 
regard that there was a higher variation in walking speed 
in the MCI group than in the HC and AD groups which can 
be explained by heterogeneity of the MCI group. It may 
therefore be valuable to make a better distinction within 
Fig. 3  Step variance (seconds 
squared indicated on the Y axis) 
during the ST (blue) and the 
DT (green) HC healthy control 
subjects, MCI mild cogni-
tive impairment subjects, AD 
Alzheimer’s disease subjects, 
ST single-task condition, DT 
dual-task condition
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the MCI group, e.g., between non-amnestic and amnestic 
MCI patients, in future research. Related to this issue is the 
fact that many studies on dual tasking, including the pre-
sent study, have a rather small sample size which may not 
explain finding significant differences in gait parameters 
between MCI patients and healthy elderly. Additionally, 
some of the participants may have suffered from vascular 
pathology for which it was difficult to control but which 
may explain the changes detected in the data.
Even though we did not find significant differences in 
dual tasking between HC and MCI patients, we believe 
that the findings of the present study warrant more 
research on the interaction between cognitive function 
and motor performance as an early indicator of cogni-
tive decline. Future research would benefit from using a 
waist-worn rather than a wrist-worn accelerometer. Fur-
thermore, we believe that future research would benefit 
from comparing a body-worn actigraph with other tech-
nologies used for gait analyses. As recently stated in the 
review by Schwenk et  al., no standardized “sensitive 
technology exists for use within routine clinical care that 
would objectively quantify relevant gait parameters for 
indicating frailty status” [37]. As stated above, a more 
practical and low-cost solution for gait analysis would be 
very valuable for clinical practice. In addition, interest-
ing topics for further research on the link between motor 
function and cognitive function in elderly with cognitive 
impairment include the relation between dual-task perfor-
mance and an individual’s ability to carry out activities 
of daily living as a measure with higher ecologic validity. 
Moreover, it would be interesting to further explore the 
value of using wrist-worn accelerometers in a non-con-
trolled environment to provide continuous information 
about subtle changes in walking parameters that could 
be useful to monitor progression of cognitive decline. 
In non-controlled environments, wrist-worn accelerom-
eters may be preferred as they are more practical and less 
stigmatizing.
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